Canada markets open in 2 hours 14 minutes
  • S&P/TSX

    20,621.39
    -436.81 (-2.07%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.03 (-1.30%)
     
  • CAD/USD

    0.7930
    -0.0018 (-0.23%)
     
  • CRUDE OIL

    85.07
    -0.07 (-0.08%)
     
  • BTC-CAD

    42,563.34
    -2,668.50 (-5.90%)
     
  • CMC Crypto 200

    769.42
    +526.74 (+217.05%)
     
  • GOLD FUTURES

    1,839.20
    +7.40 (+0.40%)
     
  • RUSSELL 2000

    1,987.92
    -36.12 (-1.78%)
     
  • 10-Yr Bond

    1.7470
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,371.75
    -54.75 (-0.38%)
     
  • VOLATILITY

    30.36
    +4.77 (+18.64%)
     
  • FTSE

    7,404.58
    -89.55 (-1.19%)
     
  • NIKKEI 225

    27,588.37
    +66.11 (+0.24%)
     
  • CAD/EUR

    0.7009
    +0.0005 (+0.07%)
     

Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • EVLO

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that management will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th, 2021 at 6:20 a.m. ET (11:20 a.m. GMT).

A live audio webcast of the presentation will be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. A replay of the webcast will be available for approximately 30 days following the presentation.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contacts
Investors:
Kendra Sweeney, 239-877-7474
ksweeney@evelobio.com

Media:
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting